Glycomics or Glycobiology Market Report 2026

The glycomics or glycobiology market size has grown rapidly in recent years. It will grow from $2.13 billion in 2025 to $2.49 billion in 2026 at a compound annual growth rate (CAGR) of 17.1%. The growth in the historic period can be attributed to advances in carbohydrate chemistry, growth of life sciences research, expansion of academic research funding, early biomolecule characterization, development of analytical instruments.

The glycomics or glycobiology market size is expected to see rapid growth in the next few years. It will grow to $4.66 billion in 2030 at a compound annual growth rate (CAGR) of 17%. The growth in the forecast period can be attributed to precision medicine expansion, pharmaceutical R&D investments, demand for biomarker discovery, technological advances in mass spectrometry, increased translational research. Major trends in the forecast period include expansion of glycan-based biological research, increased use of glycomics in drug discovery, growing demand for advanced glycan analysis tools, rising integration of glycobiology in diagnostics, increased academic and industrial collaborations.

Increasing demand for pharmaceutical products is expected to drive the growth of the glycomics or glycobiology market in the coming years. Pharmaceutical products are medications formulated to diagnose, prevent, treat, or cure diseases and medical conditions in humans or animals. Glycomics and glycobiology play a critical role in pharmaceutical development by providing insights into disease mechanisms, identifying therapeutic targets, and optimizing drug design and efficacy across a wide range of medical conditions. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, up from six in 2022. The 2023 approvals also included seven cancer drugs and three treatments for other diseases and conditions. Therefore, the increasing demand for pharmaceutical products is driving the growth of the glycomics or glycobiology market.

Major companies in the glycobiology market are focusing on developing innovative solutions, such as glycan-display platforms, to accelerate the discovery of carbohydrate-based therapeutics and vaccines. Glycan-display platforms are technologies that present diverse sugar molecules (glycans) on surfaces or scaffolds to study their interactions with proteins, cells, or pathogens for drug and vaccine development. For instance, in October 2024, CD BioGlyco, a US-based biotechnology company, launched its Glycan Display Platform, an integrated technology offering multiple modalities - including traditional glycan arrays, cell-based glycan display, neoglycolipid (NGL) display, liquid glycan arrays (LiGA), glyco-phage display, and de novo glycan display - to support a wide range of glycobiology research applications such as drug discovery and glycan-protein interaction studies. This platform uses synthesized or natural glycans and presents them on carriers such as lipids, phage particles, or engineered cells, allowing researchers to examine glycan binding properties under various contexts (e.g., fluid vs. immobilized, monovalent vs. multivalent). These features enable high-throughput screening, precise control over glycan density and presentation, and greater physiological relevance compared to traditional glycan microarrays that immobilize glycans on rigid surfaces.

In June 2025, Crescent Biopharma Inc., a US-based biotechnology company, acquired GlycoMimetics for an undisclosed amount. Through this acquisition, Crescent aims to expand its pipeline with GlycoMimetics’ portfolio of glycomimetic therapies targeting rare blood disorders and oncology indications. Crescent Biopharma Inc. specializes in glycobiology, particularly in developing glycobiology-based therapeutic solutions.

Major companies operating in the glycomics or glycobiology market are Aligent Technologies Inc., Bruker Corporation, Merck Co. & KgaA, New England Biolabs Inc., Danaher Corporation, Shimadzu Corporation, ProZyme Inc., Takara Bio Inc., Asparia Glycomics SL, Lectenz Bio, Chemily Glycoscience LLC, Z Biotech LLC, RayBiotech Inc., Thermo Fisher Scientific Inc., Promega Corporation, Bio-Techne Corp., AMS Bio LLC, Ludger Ltd., CD BioGlyco Ltd., GlycoDiag SAS, Kode Biotech Limited, Glyxera GmBH, Glycomix Ltd., R&D Systems Inc.

North America was the largest region in the glycomics or glycobiology market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomics or glycobiology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glycomics or glycobiology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the glycomics or glycobiology market by increasing costs of imported enzymes, reagents, analytical instruments, and laboratory consumables. Academic institutes and pharmaceutical companies are most affected due to dependence on imported research tools, particularly in North America and Europe. These tariffs raise research costs but encourage local manufacturing of laboratory reagents and instruments.

The glycomics or glycobiology market research report is one of a series of new reports that provides glycomics or glycobiology market statistics, including glycomics or glycobiology industry global market size, regional shares, competitors with a glycomics or glycobiology market share, detailed glycomics or glycobiology market segments, market trends and opportunities, and any further data you may need to thrive in the glycomics or glycobiology industry. This glycomics or glycobiology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Glycomics, also known as glycobiology, is the study of the structure, biosynthesis, and biological functions of saccharides, including sugar chains or glycans, which are widely found in nature. Glycobiology investigates glycans to understand their structure, production, and biological roles.

The primary products in glycomics or glycobiology include enzymes, kits, reagents and chemicals, instruments, and carbohydrates. Enzymes are biological polymers that catalyze biochemical reactions. These products are applied in various areas, such as drug discovery and development, disease diagnostics, and more, and are used by academic research institutes, pharmaceutical and biotechnology companies, and clinical laboratories.

The glycomics or glycobiology market includes revenues earned by entities by maintaining tissue structure, porosity, and integrity. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.